Monday's Health Winners & Losers

Acorda Therapeutics(ACOR Quote) saw its shares soar after the company reported positive results from a late-stage clinical trial of its multiple sclerosis drug Fampridine-SR. The trial dealt with how the drug could advance the walking abilities of MS patients.

Acorda said the findings of three separate criteria were statistically significant. Shares of Acorda more than tripled, rising 243% to $7.62.

GPC Biotech(GPCB Quote) and Pharmion(PHRM Quote) were higher after a late-stage trial produced hopeful results.

GPC said certain previously treated patients with prostate cancer taking the company's lead product candidate satraplatin plus prednisone saw a 40% reduction in the risk of disease progression compared with those on a placebo and prednisone. GPC rose 35.7% to $19, and Pharmion was up 18.8% to $21.40.

Orchid Cellmark(ORCH Quote) won contracts with the London, Kent and Sussex police forces, worth a combined $3.5 million a year, sending its shares 4.7% higher to $2.45.

Among other movers were Vertex Pharmaceuticals(VRTX Quote), up 1% to $32, and Usana Health Sciences(USNA Quote), up 1.5% to $45.99. Medtronic(MDT Quote) fell 1% to $46.12, Celgene(CELG Quote) lost 1.9% to $41.19, and Genzyme(GENZ Quote) dipped 1.1% to $64.86.

InterMune(ITMN Quote) was 1.6% lower to $16.50, St. Jude Medical(STJ Quote) fell 3.1% to $34.51, Tercica(TRCA Quote) sank 2.5% to $4.94, Hi-Tech Pharmacal(HITK Quote) was off 2% to $13.58, and Caraco Pharmaceutical Laboratories(CPD Quote) lost 1.6% to $10.47.